Dr. Peixuan Guo was the first to prove the concept of RNA nanotechnology, has held three Endowed Chair Professor positions at three prestigious universities including the College of Pharmacy at the University of Kentucky; and the College of Pharmacy at The Ohio State University (OSU), and was a Distinguished Faculty Scholar of Purdue. Currently he is Sylvan G. Frank Endowed Chair Professor in Pharmaceutics and Drug Delivery; the director of the Center of RNA Nanobiotech and Nanomedicine at OSU; the president of the International Society of RNA Nanotechnology and Nanomedicine (ISRNN). He is also the Chairman of the Board of Directors for ExonanoRNA LLC, and Foshan Weina Biomedicine Inc both focusing on the development of RNA therapeutics for cancers using the RNA Nanotechnology he invented and leads internationally. He received his Ph.D. in Microbiology and Genetics from University of Minnesota, then postdoctoral training at NIH under Bernard Moss, a member of the National Academy of Science. He was an Assistant Professor of molecular virology at Purdue in 1990, tenured in 1993, became full Professor in 1997 and was honored as a Purdue Distinguished Faculty Scholar in 1998. He was the Director of NIH Nanomedicine Development Center from 2006-2011 and the director of NCI Cancer Nanotechnology Platform Partnership Program on RNA Nanotechnology for Cancer Therapy from 2012-2017. As early as 1987 he envisioned that cells have many small RNA molecules with undiscovered novel functions, and named them “sRNA” (Guo et al. A small viral RNA is required for in vitro packaging of bacteriophage phi29 DNA. Science 1987; 236:690). He invented meteor to produce function mRNA capping enzyme (PNAS, 1991) that is used currently in the production of mRNA vaccine for COVID-19. He also constructed the first viral DNA packaging motor (PNAS 1986); was the first to report that viral DNA packaging is driven by ATPase, and identified the protein sequence for ATP binding (JBC 1986) that is the same sequence motif that 8 years later James Walker received his Novel Price in 1995; determined that one ATP is used to package two bp of dsDNA (JBC 1986); revealed pRNA hexamer (Mol Cell 1998) that has led to the emergence of the field of RNA Nanotech; pioneered RNA nanotechnology (Mol Cell 1998, featured in Cell; and 4 papers in Nature Nanotech 2010,2011,2018); developed a TIRF Photobleaching dual imaging System to count single-fluorophores (EMBOJ 2007); incorporated phi29 motor channel into membrane (Nature Nanotech 2009) for single pore sensing and RNA and peptide sequencing (licensed to Oxford Nanopore); discovered a third class of biomotor using revolution mechanism; developed approaches for ultra-potent drug development. He was honored for Pfizer Distinguished Faculty Award; Purdue Faculty Scholar Award; Lions Club Cancer Res Award; Distinguished Alumni of U of Minnesota; 100 Years Distinguished Chinese Alumni of U of Minnesota. He has been editor or on the editorial board of 7 nanotech journals including the Executive Deputy Editor of Molecular Therapy/Nucleic Acids and the co-founder of Nanomedicine BMN. He was reported numerous times by TV or media such as ABC, NBC, ACS; featured by NIH, NSF, MSNBC, NCI and ScienceNow as well as by NIH director Francis Collins’ office. He has been the organizer or founding chair of 8 international conferences and GRC conferences on RNA Nanotechnology; and was previously a member of two prominent national nanotech initiatives by NSF, NIH, National Council of Nanotechnology and NIST, as well as the member of two NIH steering committees in nanotechnology. Committee member for the 2019-2020 Life-Time Achievement Award for the American Association for Cancer Research (AACR).